

MARKET REPORT



Diabetes Therapeutics Market by Product [Injectables (Insulin, Glucagon-like Peptide-1 (GLP-1) Receptor Agonists, and Amylinomimetic Drugs) and Oral-antidiabetic Drugs (OAD) (Biguanides, Sulfonylureas, Thiazolidinediones, Alpha-glucosidase Inhibitors, Dipeptidyl Peptidase IV (DPP-4) Inhibitors, Meglitinides, and Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors)] - Global Opportunity Analysis and

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Diabetes Therapeutics Market by Product [Injectables (Insulin, Glucagon-like Peptide-1 (GLP-1) Receptor Agonists, and Amylinomimetic Drugs) and Oral-antidiabetic Drugs (OAD) (Biguanides, Sulfonylureas, Thiazolidinediones, Alpha-glucosidase Inhibitors, Dipeptidyl Peptidase IV (DPP-4) Inhibitors, Meglitinides, and Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors)] - Global Opportunity Analysis and

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1300 321501 or **Email:** reportstore@bioportfolio.com

Diabetes Therapeutics Market by Product [Injectables (Insulin, Glucagon-like Peptide-1 (GLP-1) Receptor Agonists, and Amylinomimetic Drugs) and Oral-antidiabetic Drugs (OAD) (Biguanides, Sulfonylureas, Thiazolidinediones, Alpha-glucosidase Inhibitors, Dipeptidyl Peptidase IV (DPP-4) Inhibitors, Meglitinides, and Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors)] - Global Opportunity Analysis and

The global diabetes therapeutics market was valued at \$66,993 million in 2016, and is estimated to reach \$186,842 million by 2023, growing at a CAGR of 16.0% from 2017 to 2023. Diabetes therapeutics are drugs used by diabetic patients to restore the blood glucose metabolism to a normal state.

The factors that drive the global diabetes therapeutics market include rise in geriatric population, increase in prevalence of diabetes worldwide, sedentary lifestyle of people, development of affordable & effective diabetes therapeutics, growth in awareness among people about self-management of diabetes, and support from the government. However, side effects of diabetic drugs and stringent approval process for the same restrict the market growth. Moreover, surge in awareness about diabetes care and market potential in developing regions are expected to provide numerous opportunities for market growth.

The global diabetes therapeutics market is segmented on the basis of product and region. Based on product, it is bifurcated into injectable and oral-antidiabetic drugs (OAD). Injectable are further categorized into insulin, glucagon-like peptide-1 (GLP-1) receptor agonists, and amylinomimetic drug. Oral-antidiabetic drugs (OAD) segment is further divided into biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, dipeptidyl peptidase IV (DPP-4) inhibitors, meglitinides, and sodium-glucose cotransporter-2 (SGLT2) inhibitors. Based on region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the market with current trends and future estimations from 2016 to 2023 to elucidate the imminent investment pockets.

Comprehensive analysis of factors that drive and restrict the growth of the market is provided.

Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global and regional scale are provided.

Key market players are profiled and their strategies are analyzed thoroughly, which help understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

BY PRODUCT

Injectables

Insulin

Glucagon-like Peptide-1 (GLP-1) Receptor Agonists/Incretin Mimetics

Amylin Analogue/Amylinomimetic Drugs

Oral-antidiabetic Drugs (OAD)

Biguanides

Sulfonylureas

Thiazolidinediones

Alpha-glucosidase Inhibitors

Dipeptidyl Peptidase IV (DPP-4) Inhibitors/Gliptins

Meglitinides

Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors/Gliflozins

BY REGION

North America

U.S.

Canada

Mexico

Europe

Germany

UK

France

Spain

Italy

Rest of Europe

Asia-Pacific

Japan

China

India

Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

AstraZeneca plc
Boehringer Ingelheim GmbH
Eli Lilly and Company
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Novo Nordisk
Sanofi S.A.
Takeda Pharmaceutical Company Limited

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)

Astellas Pharma Inc.
Biocon Limited
Diasome Pharmaceuticals, Inc.
Generex Biotechnology Corp.
MannKind Corporation
Pfizer Inc.

Additional Details

Publisher : Allied Market Research

<https://www.bioportfolio.co.uk/product/123323-reportstore@bioportfolio.com> to order

Reference : LI 173542
Number of Pages : 170
Report Format : PDF
Publisher Information :



AlliedMarket Research
Diligent Intelligence - Improved Growth

BioPortfolio
Life Science Healthcare and Pharmaceutical
Market Research and Corporate Data

Best Prices Guaranteed

bioportfolio.co.uk

Table Of Contents for Diabetes Therapeutics Market by Product [Injectables (Insulin, Glucagon-like Peptide-1 (GLP-1) Receptor Agonists, and Amylinomimetic Drugs) and Oral-antidiabetic Drugs (OAD) (Biguanides, Sulfonylureas, Thiazolidinediones, Alpha-glucosidase Inhibitors, Dipeptidyl Peptidase IV (DPP-4) Inhibitors, Meglitinides, and Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors)] - Global Opportunity Analysis and [Report Updated: 01-08-2017]

- CHAPTER 1 INTRODUCTION1.1. REPORT DESCRIPTION1.2. KEY BENEFITS FOR STAKEHOLDERS1.3. KEY MARKET SEGMENTS1.4. RESEARCH METHODOLOGY1.4.1. Secondary research1.4.2. Primary research1.4.3. Analyst tools and modelsCHAPTER 2 EXECUTIVE SUMMARY2.1. KEY FINDINGS OF THE STUDY2.2. CXO PERSPECTIVECHAPTER 3 MARKET OVERVIEW3.1. MARKET DEFINITION AND SCOPE3.2. KEY FINDINGS3.2.1. Top investment pockets3.2.2. Top winning strategies3.2.2.1. Competitive intelligence of companies and their strategies3.3. MARKET SHARE ANALYSIS, 20163.4. MARKET DYNAMICS3.4.1. Drivers3.4.2. Restraints3.4.3. Opportunities3.4.4. Impact analysis3.5. CLINICAL TRIALSCHAPTER 4 GLOBAL DIABETES THERAPEUTICS MARKET, BY PRODUCT4.1. OVERVIEW4.1.1. Market size and forecast4.2. INJECTABLES4.2.1. Insulin4.2.1.1. Market size and forecast4.2.2. Glucagon-like peptide-1 (GLP-1) receptor agonists4.2.2.1. Market size and forecast4.2.3. Amylinomimetic drug4.2.3.1. Market size and forecast4.2.4. Key market trends4.2.5. Growth factors and opportunities4.2.6. Market size and forecast4.3. ORAL-ANTIDIABETIC DRUGS (OAD)4.3.1. Biguanides4.3.1.1. Market size and forecast4.3.2. Sulfonylureas4.3.2.1. Market size and forecast4.3.3. Thiazolidinediones4.3.3.1. Market size and forecast4.3.4. Alpha-glucosidase inhibitors4.3.4.1. Market size and forecast4.3.5. Dipeptidyl Peptidase IV (DPP-4) inhibitors4.3.5.1. Market size and forecast4.3.6. Meglitinides4.3.6.1. Market size and forecast4.3.7. Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors4.3.7.1. Market size and forecast4.3.8. Key market trends4.3.9. Growth factors and opportunities4.3.10. Market size and forecastCHAPTER 5 DIABETES THERAPEUTICS MARKET, BY REGION5.1. OVERVIEW5.1.1. Market size and forecast5.2. NORTH AMERICA5.2.1. Key market trends5.2.2. Key growth factors and opportunities5.2.3. Market size and forecast5.2.4. U.S.5.2.5. Canada5.2.6. Mexico5.3. EUROPE5.3.1. Key market trends5.3.2. Key growth factors and opportunities5.3.3. Market size and forecast5.3.4. Germany5.3.5. France5.3.6. UK5.3.7. Italy5.3.8. Spain5.3.9. Rest of Europe5.4. ASIA-PACIFIC5.4.1. Key market trends5.4.2. Key growth factors and opportunities5.4.3. Market size and forecast5.4.4. Japan5.4.5. China5.4.6. India5.4.7. Australia5.4.8. South Korea5.4.9. Rest of Asia-Pacific5.5. LAMEA5.5.1. Key market trends5.5.2. Key growth factors and opportunities5.5.3. Market size and forecast5.5.4. Brazil5.5.5. South Africa5.5.6. Saudi Arabia5.5.7. Rest of LAMEACHAPTER 6 COMPANY PROFILES6.1. ASTRAZENECA PLC6.1.1. Company overview6.1.2. Operating business segments6.1.3. Business performance6.1.4. Key strategic moves and developments6.2. BOEHRINGER INGELHEIM GMBH6.2.1. Company overview6.2.2. Operating business segments6.2.3. Business performance6.2.4. Key strategic moves and developments6.3. ELI LILLY AND COMPANY6.3.1. Company overview6.3.2. Operating business segments6.3.3. Key strategic moves and developments6.4. GLAXOSMITHKLINE PLC6.4.1. Company overview6.4.2. Operating business segments6.4.3. Business performance6.4.4. Key strategic moves and developments6.5. JOHNSON & JOHNSON6.5.1. Company overview6.5.2. Operating business segments6.5.3. Business performance6.5.4. Key strategic moves and developments6.6. MERCK & CO., INC.6.6.1. Company overview6.6.2. Operating business segments6.6.3. Business performance6.6.4. Key strategic moves and developments6.7. NOVARTIS AG6.7.1. Company overview6.7.2. Operating business segments6.7.3. Business performance6.7.4. Key strategic moves and developments6.8. NOVO NORDISK6.8.1. Company overview6.8.2. Operating business segments6.8.3. Business performance6.8.4. Key strategic moves and developments6.9. SANOFI S.A.6.9.1. Company overview6.9.2.

Operating business segments6.9.3. Business performance6.9.4. Key strategic moves and developments6.10.
TAKEDA PHARMACEUTICAL COMPANY LIMITED6.10.1. Company overview6.10.2. Operating business
segments6.10.3. Business performance6.10.4. Key strategic moves and developments

List Of Tables in Diabetes Therapeutics Market by Product [Injectables (Insulin, Glucagon-like Peptide-1 (GLP-1) Receptor Agonists, and Amylinomimetic Drugs) and Oral-antidiabetic Drugs (OAD) (Biguanides, Sulfonylureas, Thiazolidinediones, Alpha-glucosidase Inhibitors, Dipeptidyl Peptidase IV (DPP-4) Inhibitors, Meglitinides, and Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors)] - Global Opportunity Analysis and [Report Updated: 01-08-2017]

TABLE 1. GLOBAL DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 (\$MILLION)

TABLE 2. GLOBAL INJECTABLE DIABETES THERAPEUTICS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 3. DIABETES INJECTABLE THERAPEUTICS MARKET, BY REGION, 2016-2023 (\$MILLION)

TABLE 4. GLOBAL OAD DIABETES THERAPEUTICS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 5. GLOBAL OAD DIABETES THERAPEUTICS MARKET, BY REGION, 2016-2023 (\$MILLION)

TABLE 6. DIABETES THERAPEUTICS MARKET, BY REGION, 2016-2023 (\$MILLION)

TABLE 7. NORTH AMERICA DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 (\$MILLION)

TABLE 8. NORTH AMERICA DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 (\$MILLION)

TABLE 9. EUROPE DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 (\$MILLION)

TABLE 10. EUROPE DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 (\$MILLION)

TABLE 11. ASIA-PACIFIC DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 (\$MILLION)

TABLE 12. ASIA-PACIFIC DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 (\$MILLION)

TABLE 13. LAMEA DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 (\$MILLION)

TABLE 14. LAMEA DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 (\$MILLION)

TABLE 15. ASTRAZENECA: COMPANY SNAPSHOT

TABLE 16. BOEHRINGER: COMPANY SNAPSHOT

TABLE 17. ELI LILLY: COMPANY SNAPSHOT

TABLE 18. GLAXOSMITHKLINE: COMPANY SNAPSHOT

TABLE 19. J&J: COMPANY SNAPSHOT

TABLE 20. MERCK: COMPANY SNAPSHOT

TABLE 21. NOVARTIS: COMPANY SNAPSHOT

<https://www.bioportfolio.co.uk/product/123323>
reportstore@bioportfolio.com to order

TABLE 22. NOVO NORDISK: COMPANY SNAPSHOT

TABLE 23. SANOFI: COMPANY SNAPSHOT

TABLE 24. TAKEDA: COMPANY SNAPSHOT

List Of Figures, Charts and Diagrams in Diabetes Therapeutics Market by Product [Injectables (Insulin, Glucagon-like Peptide-1 (GLP-1) Receptor Agonists, and Amylinomimetic Drugs) and Oral-antidiabetic Drugs (OAD) (Biguanides, Sulfonylureas, Thiazolidinediones, Alpha-glucosidase Inhibitors, Dipeptidyl Peptidase IV (DPP-4) Inhibitors, Meglitinides, and Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors)] - Global Opportunity Analysis and [Report Updated: 01-08-2017]

FIGURE 1. DIABETES THERAPEUTICS MARKET SEGMENTATION

FIGURE 2. TOP INVESTMENT POCKETS

FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, (2014-2016)

FIGURE 4. TOP WINNING STRATEGIES: NATURE AND TYPE

FIGURE 5. TOP COMPANIES AND THEIR STRATEGIES

FIGURE 6. DETAILED STRUCTURE OF COMPANIES AND NATURE OF STRATEGIES

FIGURE 7. DETAILED STRUCTURE OF COMPANIES AND TYPE OF STRATEGIES

FIGURE 8. MARKET SHARE ANALYSIS, DIABETES THERAPEUTICS MARKET, 2016

FIGURE 9. IMPACT ANALYSIS: DIABETES THERAPEUTICS MARKET

FIGURE 10. TOTAL NUMBER OF CLINICAL TRIALS IN DIABETES THERAPEUTICS MARKET

FIGURE 11. INSULIN MARKET, 2016-2023, (\$MILLION)

FIGURE 12. GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS/INCRETIN MIMETICS MARKET, 2016-2023, (\$MILLION)

FIGURE 13. AMYLIN ANALOGUE/AMYLINOMIMETIC DRUG MARKET, 2016-2023, (\$MILLION)

FIGURE 14. BIGUANIDES MARKET, 2016-2023, (\$MILLION)

FIGURE 15. SULFONYLUREAS MARKET, 2016-2023, (\$MILLION)

FIGURE 16. THIAZOLIDINEDIONES MARKET, 2016-2023, (\$MILLION)

FIGURE 17. ALPHA-GLUCOSIDASE INHIBITORS MARKET, 2016-2023, (\$MILLION)

FIGURE 18. DIPEPTIDYL PEPTIDASE IV (DPP-4) INHIBITORS /GLIPTINS MARKET, 2016-2023, (\$MILLION)

FIGURE 19. MEGLITINIDES MARKET, 2016-2023, (\$MILLION)

FIGURE 20. SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS /GLIFLOZINS MARKET, 2016-2023,

(\$MILLION)

FIGURE 21. U.S. DIABETES THERAPEUTICS MARKET, 2016-2023, (\$MILLION)

FIGURE 22. CANADA DIABETES THERAPEUTICS MARKET, 2016-2023, (\$MILLION)

FIGURE 23. MEXICO DIABETES THERAPEUTICS MARKET, 2016-2023, (\$MILLION)

FIGURE 24. GERMANY DIABETES THERAPEUTICS MARKET, 2016-2023, (\$MILLION)

FIGURE 25. FRANCE DIABETES THERAPEUTICS MARKET, 2016-2023, (\$MILLION)

FIGURE 26. UK DIABETES THERAPEUTICS MARKET, 2016-2023, (\$MILLION)

FIGURE 27. ITALY DIABETES THERAPEUTICS MARKET, 2016-2023, (\$MILLION)

FIGURE 28. SPAIN DIABETES THERAPEUTICS MARKET, 2016-2023, (\$MILLION)

FIGURE 29. REST OF EUROPE DIABETES THERAPEUTICS MARKET, 2016-2023, (\$MILLION)

FIGURE 30. JAPAN DIABETES THERAPEUTICS MARKET, 2016-2023, (\$MILLION)

FIGURE 31. CHINA DIABETES THERAPEUTICS MARKET, 2016-2023, (\$MILLION)

FIGURE 32. INDIA DIABETES THERAPEUTICS MARKET, 2016-2023, (\$MILLION)

FIGURE 33. AUSTRALIA DIABETES THERAPEUTICS MARKET, 2016-2023, (\$MILLION)

FIGURE 34. SOUTH KOREA DIABETES THERAPEUTICS MARKET, 2016-2023, (\$MILLION)

FIGURE 35. REST OF ASIA-PACIFIC DIABETES THERAPEUTICS MARKET, 2016-2023, (\$MILLION)

FIGURE 36. BRAZIL DIABETES THERAPEUTICS MARKET, 2016-2023, (\$MILLION)

FIGURE 37. SOUTH AFRICA DIABETES THERAPEUTICS MARKET, 2016-2023, (\$MILLION)

FIGURE 38. SAUDI ARABIA DIABETES THERAPEUTICS MARKET, 2016-2023, (\$MILLION)

FIGURE 39. REST OF LAMEA DIABETES THERAPEUTICS MARKET, 2016-2023, (\$MILLION)

How to Buy...

Diabetes Therapeutics Market by Product [Injectables (Insulin, Glucagon-like Peptide-1 (GLP-1) Receptor Agonists, and Amylinomimetic Drugs) and Oral-antidiabetic Drugs (OAD) (Biguanides, Sulfonylureas, Thiazolidinediones, Alpha-glucosidase Inhibitors, Dipeptidyl Peptidase IV (DPP-4) Inhibitors, Meglitinides, and Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors)] - Global Opportunity Analysis and [Report Updated: 01-08-2017]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/123323>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at reportstore@bioportfolio.com or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$3440** | Single User Price
- \$5910** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.